Jacobs Levy Equity Management Inc. Sells 118,375 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

Jacobs Levy Equity Management Inc. lessened its position in Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 16.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 580,783 shares of the company's stock after selling 118,375 shares during the period. Jacobs Levy Equity Management Inc. owned about 1.10% of Kodiak Sciences worth $1,516,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Acadian Asset Management LLC lifted its holdings in Kodiak Sciences by 14.1% during the 2nd quarter. Acadian Asset Management LLC now owns 1,965,449 shares of the company's stock worth $4,614,000 after buying an additional 242,559 shares during the period. Vanguard Group Inc. lifted its stake in Kodiak Sciences by 0.7% in the first quarter. Vanguard Group Inc. now owns 1,654,448 shares of the company's stock valued at $8,702,000 after buying an additional 10,978 shares during the period. Renaissance Technologies LLC lifted its position in shares of Kodiak Sciences by 21.9% during the 2nd quarter. Renaissance Technologies LLC now owns 708,800 shares of the company's stock valued at $1,666,000 after acquiring an additional 127,400 shares during the period. GSA Capital Partners LLP bought a new position in Kodiak Sciences during the third quarter worth $751,000. Finally, FMR LLC grew its holdings in Kodiak Sciences by 26.4% in the third quarter. FMR LLC now owns 200,971 shares of the company's stock worth $525,000 after purchasing an additional 41,987 shares during the period. 89.06% of the stock is owned by institutional investors.

Kodiak Sciences Stock Up 27.2 %

Kodiak Sciences stock traded up $2.13 during mid-day trading on Monday, reaching $9.96. 1,545,334 shares of the company's stock were exchanged, compared to its average volume of 476,348. The firm has a market capitalization of $524.10 million, a PE ratio of -2.74 and a beta of 2.38. The business's fifty day simple moving average is $4.56 and its 200 day simple moving average is $3.35. Kodiak Sciences Inc. has a one year low of $2.18 and a one year high of $11.60.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on KOD shares. Barclays increased their price objective on shares of Kodiak Sciences from $3.00 to $4.00 and gave the stock an "underweight" rating in a research report on Friday, November 15th. HC Wainwright restated a "neutral" rating and issued a $3.00 target price on shares of Kodiak Sciences in a report on Friday, November 15th. Finally, Jefferies Financial Group raised Kodiak Sciences from a "hold" rating to a "buy" rating and set a $20.00 price target for the company in a research report on Monday. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $6.80.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.